Protara Therapeutics CMO Resigns, Interim Successor Named
Company Announcements

Protara Therapeutics CMO Resigns, Interim Successor Named

Protara Therapeutics (TARA) just unveiled an announcement.

Protara Therapeutics, Inc. has announced the resignation of their Chief Medical Officer, Dr. Jathin Bandari, effective April 11, 2024, as he shifts focus to other opportunities and academic pursuits. Although leaving, Dr. Bandari will still offer consulting services to Protara until July 11, 2024. Under the terms of his separation agreement, he will receive a lump sum of his base salary for nine months, part of his annual bonus, and other financial benefits, including vested stock options. In the interim, Dr. Jacqueline Zummo will take charge of the clinical trial teams with Dr. Richard Levy’s guidance, while the company searches for a new CMO.

Find detailed analytics on TARA stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyProtara Therapeutics reports Q3 EPS (50c), consensus (52c)
TheFlyProtara Therapeutics sees cash runway into 2026
Christine BrownProtara Therapeutics, Inc. (TARA) Q3 Earnings Cheat Sheet
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App